Alto Neuroscience (ANRO) Competitors $4.27 -0.21 (-4.69%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ANRO vs. ZVRA, ESPR, RGNX, SLRN, MGTX, XERS, SIGA, RNAC, AURA, and AQSTShould you be buying Alto Neuroscience stock or one of its competitors? The main competitors of Alto Neuroscience include Zevra Therapeutics (ZVRA), Esperion Therapeutics (ESPR), REGENXBIO (RGNX), Acelyrin (SLRN), MeiraGTx (MGTX), Xeris Biopharma (XERS), SIGA Technologies (SIGA), Cartesian Therapeutics (RNAC), Aura Biosciences (AURA), and Aquestive Therapeutics (AQST). These companies are all part of the "pharmaceutical products" industry. Alto Neuroscience vs. Zevra Therapeutics Esperion Therapeutics REGENXBIO Acelyrin MeiraGTx Xeris Biopharma SIGA Technologies Cartesian Therapeutics Aura Biosciences Aquestive Therapeutics Zevra Therapeutics (NASDAQ:ZVRA) and Alto Neuroscience (NYSE:ANRO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, community ranking, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk. Does the MarketBeat Community believe in ZVRA or ANRO? Zevra Therapeutics received 15 more outperform votes than Alto Neuroscience when rated by MarketBeat users. Likewise, 100.00% of users gave Zevra Therapeutics an outperform vote while only 82.35% of users gave Alto Neuroscience an outperform vote. CompanyUnderperformOutperformZevra TherapeuticsOutperform Votes29100.00% Underperform VotesNo VotesAlto NeuroscienceOutperform Votes1482.35% Underperform Votes317.65% Do analysts prefer ZVRA or ANRO? Zevra Therapeutics currently has a consensus target price of $21.00, suggesting a potential upside of 134.11%. Alto Neuroscience has a consensus target price of $20.00, suggesting a potential upside of 368.38%. Given Alto Neuroscience's higher probable upside, analysts clearly believe Alto Neuroscience is more favorable than Zevra Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zevra Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Alto Neuroscience 0 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.63 Does the media prefer ZVRA or ANRO? In the previous week, Zevra Therapeutics had 24 more articles in the media than Alto Neuroscience. MarketBeat recorded 37 mentions for Zevra Therapeutics and 13 mentions for Alto Neuroscience. Zevra Therapeutics' average media sentiment score of 0.25 beat Alto Neuroscience's score of 0.15 indicating that Zevra Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zevra Therapeutics 10 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Alto Neuroscience 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is ZVRA or ANRO more profitable? Alto Neuroscience has a net margin of 0.00% compared to Zevra Therapeutics' net margin of -342.63%. Alto Neuroscience's return on equity of -49.28% beat Zevra Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Zevra Therapeutics-342.63% -159.54% -51.50% Alto Neuroscience N/A -49.28%-33.52% Do institutionals and insiders hold more shares of ZVRA or ANRO? 35.0% of Zevra Therapeutics shares are held by institutional investors. 2.4% of Zevra Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has better earnings and valuation, ZVRA or ANRO? Alto Neuroscience has lower revenue, but higher earnings than Zevra Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZevra Therapeutics$27.46M17.44-$46.05M-$1.97-4.55Alto Neuroscience$210K548.39-$36.31MN/AN/A SummaryZevra Therapeutics beats Alto Neuroscience on 10 of the 16 factors compared between the two stocks. Ad Wyatt Investment ResearchMy #1 Pre IPO Trade for 2025 – NAME and TICKEROne tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...The Next SpaceX Pre-IPO Get Alto Neuroscience News Delivered to You Automatically Sign up to receive the latest news and ratings for ANRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANRO vs. The Competition Export to ExcelMetricAlto NeurosciencePharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$115.16M$6.48B$5.05B$19.84BDividend YieldN/A8.12%4.97%3.50%P/E RatioN/A5.5697.3437.73Price / Sales548.39348.141,218.4218.01Price / CashN/A22.1533.5117.90Price / BookN/A7.885.804.86Net Income-$36.31M$153.61M$119.07M$985.93M7 Day Performance-7.38%-2.00%-1.83%0.45%1 Month Performance-70.12%-7.47%-3.64%1.05%1 Year PerformanceN/A31.80%31.62%24.67% Alto Neuroscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANROAlto Neuroscience3.532 of 5 stars$4.27-4.7%$20.00+368.4%N/A$120.83M$210,000.000.00N/AAnalyst RevisionZVRAZevra Therapeutics3.4632 of 5 stars$8.97flat$21.00+134.1%+100.2%$478.78M$27.46M-4.5565Analyst ForecastAnalyst RevisionESPREsperion Therapeutics3.9536 of 5 stars$2.41flat$8.17+238.9%+97.5%$474.86M$116.33M-3.77240Analyst ForecastRGNXREGENXBIO4.4242 of 5 stars$9.63+0.7%$35.64+270.1%-51.9%$473.65M$90.24M-1.91344Analyst ForecastAnalyst RevisionSLRNAcelyrin3.3895 of 5 stars$4.43-6.1%$11.50+159.6%-50.2%$473.54MN/A-1.80135Analyst RevisionPositive NewsMGTXMeiraGTx4.3185 of 5 stars$5.82-2.7%$23.50+303.8%+2.8%$467.36M$14.02M0.00300Analyst ForecastXERSXeris Biopharma3.9457 of 5 stars$3.06+1.7%$4.87+59.0%+68.1%$448.73M$163.91M0.00290SIGASIGA Technologies0.9671 of 5 stars$6.25-0.2%N/A+20.9%$446.99M$139.92M5.2140Analyst RevisionRNACCartesian Therapeutics2.1866 of 5 stars$16.94-3.5%$42.33+149.9%+0.8%$446.03M$26M-0.3237Insider TradeAURAAura Biosciences3.5197 of 5 stars$8.75-1.9%$23.00+162.9%+5.3%$445.57MN/A-5.0650Insider TradeAnalyst RevisionAQSTAquestive Therapeutics2.266 of 5 stars$4.74-1.7%$9.80+107.0%+164.5%$439.48M$50.58M-10.52160Short Interest ↓Positive News Related Companies and Tools Related Companies Zevra Therapeutics Competitors Esperion Therapeutics Competitors REGENXBIO Competitors Acelyrin Competitors MeiraGTx Competitors Xeris Biopharma Competitors SIGA Technologies Competitors Cartesian Therapeutics Competitors Aura Biosciences Competitors Aquestive Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:ANRO) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alto Neuroscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alto Neuroscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
